Full Text
REGD. No. D. L.-33004/99
The Gazette of India
CG-DL-E-28032025-262058
EXTRAORDINARY
PART II-Section 3-Sub-section (ii)
PUBLISHED BY AUTHORITY
No. 1467]
NEW DELHI, THURSDAY, MARCH 27, 2025/CHAITRA 6, 1947
2189 GI/2025
(1)
MINISTRY OF CHEMICALS AND FERTILIZERS
(Department of Pharmaceuticals)
NATIONAL PHARMACEUTICAL PRICING AUTHORITY
ORDER
New Delhi, the 27th March, 2025
S.O. 1485(E). — In exercise of powers, conferred by sub paragraph (3) and (4) of paragraph 11, 14 and 16 of
the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated 30th May, 2013, S.O. 1192(E) dated 22nd March,
2016, S.O. 5249(E) dated 11th November, 2022 issued by the Government of India in the Ministry of Chemicals and
Fertilizers and in supersession of the order of the Government of India in the Ministry of Chemicals and Fertilizers
(National Pharmaceutical Pricing Authority) S.O. No. 1552(E) dated 26.03.2024, 2293(E) dated 14.06.2024 and
5499(E) dated 19.12.2024 in so far as they relate to formulation packs mentioned in the Table A below, manufactured
by the manufacturers specified in Table B for specified products and pack-sizes, except in respect of things done or
omitted to be done before such supersession, the National Pharmaceutical Pricing Authority, hereby revises the price
based on Wholesale price index (WPI) of 2024 as specified in column (5) of the Table A herein below as separate
ceiling price exclusive of Goods and Services Tax applicable, if any, in respect of the scheduled formulations
specified in the corresponding entry in column (2) of the said Table with the dosage form and strength and
unit/packaging specified respectively in the corresponding entries in columns (3) and (4) thereof:
Table A
Price Revision as per Annual Wholesale Price Index (WPI) @ 1.74028% increase.
+-----+------------------+----------------------------+---------------------------------------------------+-----------------------------------+
| S1. | Medicines | Dosage form | Unit | Ceiling price (w.e.f.1.4.2025 with|
| No. | | and Strength | | WPI @ 1.74028%) (in Rs.) |
+=====+==================+============================+===================================================+===================================+
| (1) | (2) | (3) | (4) | (5) |
+-----+------------------+----------------------------+---------------------------------------------------+-----------------------------------+
| 1. | Glucose | Injection 5% | 1000ml Non Glass with special features | 96.77 |
+-----+------------------+----------------------------+---------------------------------------------------+-----------------------------------+
| 2. | Glucose | Injection 5% | 500ml Non Glass with special features | 83.70 |
+-----+------------------+----------------------------+---------------------------------------------------+-----------------------------------+
| 3. | Glucose (A) + | Injection 5% | 1000ml Non Glass with special features | 101.68 |
| | Sodium Chloride | (A) + 0.9% | | |
| | (B) | (B) | | |
+-----+------------------+----------------------------+---------------------------------------------------+-----------------------------------+
| 4. | Glucose (A) + | Injection 5% | 500ml Non Glass with special features | 87.01 |
| | Sodium Chloride | (A) + 0.9% | | |
| | (B) | (B) | | |
+-----+------------------+----------------------------+---------------------------------------------------+-----------------------------------+
| 5. | Sodium Chloride | Injection 0.9% | 100ml Non Glass with special features | 42.79 |
+-----+------------------+----------------------------+---------------------------------------------------+-----------------------------------+
| 6. | Sodium Chloride | Injection 0.9% | 250ml Non Glass with special features | 63.18 |
+-----+------------------+----------------------------+---------------------------------------------------+-----------------------------------+
| 7. | Sodium Chloride | Injection 0.9% | 500ml Non Glass with special features | 89.47 |
+-----+------------------+----------------------------+---------------------------------------------------+-----------------------------------+
| 8. | Sodium Chloride | Injection 0.9% | 1000ml Non Glass with special features | 100.22 |
+-----+------------------+----------------------------+---------------------------------------------------+-----------------------------------+
TABLE 'B'
+-----+--------------------------------------------------+-------------------------------------------+
| S1. | Name of Manufacturer | Product/Brand Name |
| No. | | |
+=====+==================================================+===========================================+
| (1) | (2) | (3) |
+-----+--------------------------------------------------+-------------------------------------------+
| 1. | M/s B.Braun Medical (I) Pvt Ltd. | Ecoflac Plus bottle with Eurohead |
+-----+--------------------------------------------------+-------------------------------------------+
| 2. | M/s Amanta Healthcare Ltd. | Steriport bottle |
+-----+--------------------------------------------------+-------------------------------------------+
| 3. | M/s Aculife Healthcare Pvt Ltd. | Aculife bottle with Eurohead |
+-----+--------------------------------------------------+-------------------------------------------+
| 4. | M/s Albert David Limited | Albert David bottle with Eurohead |
+-----+--------------------------------------------------+-------------------------------------------+
| 5. | M/s Denis Chem Limited | Aquapulse with Eurohead |
+-----+--------------------------------------------------+-------------------------------------------+
| 6. | M/s Claris Life Sciences Limited | Claris bottle with Eurohead |
+-----+--------------------------------------------------+-------------------------------------------+
| 7. | M/s Fresenius Kabi India Pvt Limited | Freeflex bags |
+-----+--------------------------------------------------+-------------------------------------------+
| 8. | M/s Otsuka Pharmaceutical India Private Ltd. | Unibag |
| | (previously known as Claris Otsuka Private | |
| | Limited) | |
+-----+--------------------------------------------------+-------------------------------------------+
| 9. | M/s Aishwarya Lifesciences | Lifusion Eurohead bottle |
+-----+--------------------------------------------------+-------------------------------------------+
| 10. | M/s Baxter (India) Pvt. Ltd. | Viaflex bags |
+-----+--------------------------------------------------+-------------------------------------------+
| 11. | M/s Otsuka Pharmaceutical India Private Ltd. | Eurohead bottle |
| | (previously known as Claris Otsuka Private | |
| | Limited) | |
+-----+--------------------------------------------------+-------------------------------------------+
| 12. | M/s Fresenius Kabi India Pvt Limited | Eurohead bottle |
+-----+--------------------------------------------------+-------------------------------------------+
| 13. | M/s Axa Parenterals Ltd | Steri Drip bottle with Eurohead |
+-----+--------------------------------------------------+-------------------------------------------+
| 14. | M/s Shree Krishna Keshav Laboratories Ltd | Easyport bottle with Eurohead |
+-----+--------------------------------------------------+-------------------------------------------+
| 15. | M/s Rusoma Laboratories Pvt. Ltd. | Puradrip |
+-----+--------------------------------------------------+-------------------------------------------+
| 16. | M/s R. K. Laboratories Pvt. Ltd. | Eurohead bottle |
+-----+--------------------------------------------------+-------------------------------------------+
| 17. | M/s Eurolife Healthcare Pvt. Ltd. | Life port |
+-----+--------------------------------------------------+-------------------------------------------+
| 18. | M/s Realcade Lifescience Pvt. Ltd. | Euro head bottle |
+-----+--------------------------------------------------+-------------------------------------------+
| 19. | M/s Puniska Healthcare Pvt. Ltd [Note (b) below] | Non -PVC bag |
+-----+--------------------------------------------------+-------------------------------------------+
| 20. | M/s Abaris Healthcare Pvt. Ltd | Duo Port |
+-----+--------------------------------------------------+-------------------------------------------+
| 21. | M/s Higgs Healthcare [Note (c) below] | Aqua Drip |
+-----+--------------------------------------------------+-------------------------------------------+
| 22. | M/s Rusoma Laboratories Pvt. Ltd. | Eurohead Bottles with Brand name "Dewdrip"|
+-----+--------------------------------------------------+-------------------------------------------+
| 23. | M/s Puerto life Sciences Private Limited [Note (d)| Euro head bottle |
| | below] | |
+-----+--------------------------------------------------+-------------------------------------------+
| 24. | M/s Sachin Parenteral Pvt. Ltd. [Note (e) below] | "SAFE PORT" |
+-----+--------------------------------------------------+-------------------------------------------+
| 25. | M/s Biosynergy Lifecare Pvt. Ltd. [Note (f) below]| "BIOPORT" |
+-----+--------------------------------------------------+-------------------------------------------+
| 26. | M/s Promea Therapeutics Pvt. Ltd. [Note (g) below]| LDPE Bottle/ Non-Glass container with |
| | | special features Euro head Cap |
+-----+--------------------------------------------------+-------------------------------------------+
| 27. | M/s Puniska Injectables Private Limited | Plastic Bottle with Euro head Cap |
+-----+--------------------------------------------------+-------------------------------------------+
| 28. | M/s Jedux Parenteral Private Limited [Note (h) | JEDUX Double port with Euro head, JPORT |
| | below] | plus |
+-----+--------------------------------------------------+-------------------------------------------+
Note:
(a) The ceiling prices are applicable with effect from 1.4.2025 (ceiling prices are inclusive of Wholesale Price Index
(WPI) @ 1.74028% for the year 2024 over 2023).
(b) In case of M/s Puniska Healthcare Pvt. Ltd. mentioned in Sl. No. 19 of Table B, only the prices of the
formulations specified in Sl. No. 5, 6, 7 & 8 of Table A are applicable.
(c) In case of M/s Higgs Healthcare mentioned in Sl. No. 21 of Table B, only the prices of the formulations specified
in Sl. No. 1, 2, 3, 4, 5, 7 & 8 of Table A are applicable.
(d) In case of M/s Puerto life Sciences Private Limited mentioned in Sl. No. 23 of Table B, only the prices of the
formulations specified in Sl. No. 2, 4, 5 & 7 of Table A are applicable.
(e) In case of M/s Sachin Parenteral Pvt. Ltd. mentioned in Sl. No. 24 of Table B, only the prices of the formulations
specified in Sl. No. 2, 4, 5, 6 & 7 of Table A are applicable.
(f) In case of M/s Biosynergy Lifecare Pvt. Ltd. mentioned in Sl. No. 25 of Table B, only the prices of the
formulations specified in Sl. No. 1, 2, 3, 4, 5, 7 & 8 of Table A are applicable.
(g) In case of M/s Promea Therapeutics Pvt. Ltd. mentioned in Sl. No. 26 of Table B, only the prices of the
formulations specified in Sl. No. 2, 4, 5 & 7 of Table A are applicable.
(h) In case of M/s Jedux Parenteral Private Limited mentioned in Sl. No. 28 of Table B, only the prices of the
formulations specified in Sl. No. 1, 2, 3, 4, 5, 7 & 8 of Table A are applicable.
(i) The manufacturers of scheduled formulations, selling above said products/brands of scheduled formulations at
price higher than the ceiling price (plus Goods and Services Tax as applicable) so fixed and notified by the
Government, shall revise the prices of all such formulations downward not exceeding the ceiling price specified
in column (5) in the above table plus Goods and Services Tax as applicable, if any.
(j) The manufacturers of above-mentioned scheduled formulations having MRP lower than the ceiling price notified
vide S.O. No. 1552(E) dated 26.03.2024, 2293(E) dated 14.06.2024 and 5499(E) dated 19.12.2024 (plus Goods
and Services Tax as applicable, if any), may revise the existing M.R.P. of their formulations, on the basis of WPI
@1.74028% for year 2024 over 2023 in accordance with paragraph 16(2) of DPCO, 2013.
(k) The manufacturers may add Goods and Services Tax only if they have paid actually or if it is payable to the
Government on the ceiling price mentioned in column (5) of the above said table.
(l) Any other manufacturer claiming separate ceiling price for Non-Glass with special feature shall apply to NPPA
for separate ceiling price approval alongwith documentation and demonstrate such pack.
(m) Information about the revision, if carried out, shall be forwarded to the Government in either electronic or
physical form in Form-II within a period of fifteen days of such revision and non-submission of information
under this sub-paragraph shall be construed as non revision of maximum retail price (MRP) and the concerned
manufacturer shall be liable to deposit the amount charged over and above the pre-revised maximum retail price
(MRP), alongwith interest thereon from the date of overcharging.
(n) The ceiling price for a pack of the scheduled formulation shall be arrived at by the concerned manufacturer in
accordance with the ceiling price specified in column (5) of the above table as per provisions contained in
paragraph 11 of the Drugs (Prices Control) Order, 2013. The manufacturer shall issue a price list in Form-V
from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to
State Drug Controller and dealers.
(o) As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price
list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business
in a manner so as to be easily accessible to any person wishing to consult the same.
(p) Where an existing manufacturer of scheduled formulation with dosage or strength or both as specified in the
above table launches a new drug as per paragraph 2 (1) (u) of the DPCO, 2013 such existing manufacturer shall
apply for prior price approval of such new drug to the NPPA in Form I as specified under Schedule-II of the
DPCO, 2013.
(q) The manufacturers of above said scheduled formulations shall furnish quarterly return to the NPPA, in respect of
production / import and sale of scheduled formulations in Form-III of Schedule-II of the DPCO, 2013 through
IPDMS. Any manufacturer intending to discontinue production of above said scheduled formulation shall furnish
information to the NPPA, in respect of discontinuation of production and / or import of scheduled formulation in
Form-IV of Schedule-II of the DPCO, 2013 at least six months prior to the intended date of discontinuation.
(r) The manufacturers not complying with the ceiling price and notes specified hereinabove shall be liable to deposit
the overcharged amount along with interest thereon under the provisions of the Drugs (Prices Control) Order,
2013 read with Essential Commodities Act, 1955.
(s) Consequent to the issue of ceiling prices of such formulations as specified in column (2) of the above table in this
notification, the price order(s) fixing ceiling or retail price, if any, issued prior to the above said date of
notification, stand(s) superseded.
[PN/263/131/2025/F / F. No. 8(131)/2025/D.P./NPPA-Div.-II]
MAHAVEER SAINI, Dy. Director(Pricing)